-
1
-
-
0033152273
-
Abciximab facilitates the rate and extent of thrombolysis: Results of the thrombolysis in myocardial infarction (TIMI) 14 trial
-
E.M. Antman, R.P. Giugliano, and C.M. Gibson Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial Circulation 99 1999 2720 2732
-
(1999)
Circulation
, vol.99
, pp. 2720-2732
-
-
Antman, E.M.1
Giugliano, R.P.2
Gibson, C.M.3
-
2
-
-
0343798542
-
Trial of abciximab with and without low-dose reteplase for acute myocardial infarction
-
The SPEED Study Group
-
The SPEED Study Group Trial of abciximab with and without low-dose reteplase for acute myocardial infarction Circulation 101 2000 2788 2794
-
(2000)
Circulation
, vol.101
, pp. 2788-2794
-
-
-
3
-
-
0037028598
-
Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: The integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial
-
S.J. Brener, U. Zeymer, and A.A. Adgey Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial J Am Coll Cardiol 39 2002 377 386
-
(2002)
J Am Coll Cardiol
, vol.39
, pp. 377-386
-
-
Brener, S.J.1
Zeymer, U.2
Adgey, A.A.3
-
4
-
-
0345578676
-
Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: Results of the INTEGRIlin and Tenecteplase in acute myocardial Infarction (INTEGRITI) phase II angiographic trial
-
R.P. Giugliano, M.T. Roe, and R.A. Harrington Combination reperfusion therapy with eptifibatide and reduced-dose tenecteplase for ST-elevation myocardial infarction: results of the INTEGRIlin and Tenecteplase in acute myocardial Infarction (INTEGRITI) phase II angiographic trial J Am Coll Cardiol 41 2003 1251 1260
-
(2003)
J Am Coll Cardiol
, vol.41
, pp. 1251-1260
-
-
Giugliano, R.P.1
Roe, M.T.2
Harrington, R.A.3
-
5
-
-
0037046221
-
Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: Results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial
-
E.M. Antman, H.W. Louwerenburg, and H.F. Baars Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis In Myocardial Infarction (TIMI) 23 Trial Circulation 105 2002 1642 1649
-
(2002)
Circulation
, vol.105
, pp. 1642-1649
-
-
Antman, E.M.1
Louwerenburg, H.W.2
Baars, H.F.3
-
6
-
-
0034711702
-
Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial
-
J.A. de Lemos, E.M. Antman, and C.M. Gibson Abciximab improves both epicardial flow and myocardial reperfusion in ST-elevation myocardial infarction. Observations from the TIMI 14 trial Circulation 101 2000 239 243
-
(2000)
Circulation
, vol.101
, pp. 239-243
-
-
De Lemos, J.A.1
Antman, E.M.2
Gibson, C.M.3
-
7
-
-
0023258694
-
Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: A comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge
-
J.H. Chesebro, G. Knatterud, and R. Roberts Thrombolysis In Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge Circulation 76 1987 142 154
-
(1987)
Circulation
, vol.76
, pp. 142-154
-
-
Chesebro, J.H.1
Knatterud, G.2
Roberts, R.3
-
8
-
-
9044246670
-
TIMI frame count: A quantitative method of assessing coronary artery flow
-
C.M. Gibson, C.P. Cannon, and W.L. Daley TIMI frame count: a quantitative method of assessing coronary artery flow Circulation 93 1996 879 888
-
(1996)
Circulation
, vol.93
, pp. 879-888
-
-
Gibson, C.M.1
Cannon, C.P.2
Daley, W.L.3
-
9
-
-
0025851456
-
Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction
-
E.G. Bovill, M.L. Terrin, and D.C. Stump Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, heparin, and aspirin for acute myocardial infarction Ann. Intern. Med. 115 1991 256 265
-
(1991)
Ann. Intern. Med.
, vol.115
, pp. 256-265
-
-
Bovill, E.G.1
Terrin, M.L.2
Stump, D.C.3
-
10
-
-
0032578970
-
TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: Results of the TIMI 10B trial
-
C.P. Cannon, C.M. Gibson, and C.H. McCabe TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction: results of the TIMI 10B trial Circulation 98 1998 2805 2814
-
(1998)
Circulation
, vol.98
, pp. 2805-2814
-
-
Cannon, C.P.1
Gibson, C.M.2
McCabe, C.H.3
-
11
-
-
0033695759
-
Combination reperfusion therapy with abciximab and reduced dose reteplase: Results from TIMI 14
-
E.M. Antman, C.M. Gibson, and J.A. de Lemos Combination reperfusion therapy with abciximab and reduced dose reteplase: results from TIMI 14 Eur Heart J 21 2000 1944 1953
-
(2000)
Eur Heart J
, vol.21
, pp. 1944-1953
-
-
Antman, E.M.1
Gibson, C.M.2
De Lemos, J.A.3
-
12
-
-
0030664732
-
Differential effects of anticoagulants on the activation of platelets ex vivo
-
D.J. Schneider, P.B. Tracy, and K.G. Mann Differential effects of anticoagulants on the activation of platelets ex vivo Circulation 96 1997 2877 2883
-
(1997)
Circulation
, vol.96
, pp. 2877-2883
-
-
Schneider, D.J.1
Tracy, P.B.2
Mann, K.G.3
-
13
-
-
0030610564
-
2+ on GP IIb-IIIa interactions with integrilin: Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
-
2+ on GP IIb-IIIa interactions with integrilin: enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate Circulation 96 1997 1488 1494
-
(1997)
Circulation
, vol.96
, pp. 1488-1494
-
-
Phillips, D.R.1
Teng, W.2
Arfsten, A.3
-
14
-
-
0036498633
-
Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions
-
S.S. Kabbani, A. Aggarwal, and E.F. Terrien Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions Am J Cardiol 89 2002 647 650
-
(2002)
Am J Cardiol
, vol.89
, pp. 647-650
-
-
Kabbani, S.S.1
Aggarwal, A.2
Terrien, E.F.3
-
15
-
-
0343376106
-
The effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty
-
The RESTORE Investigators
-
The RESTORE Investigators The effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty Circulation 96 1997 1445 1453
-
(1997)
Circulation
, vol.96
, pp. 1445-1453
-
-
-
16
-
-
0035927988
-
Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization
-
E.J. Topol, D.J. Moliterno, and H.C. Herrmann Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization N Engl J Med 344 2001 1888 1894
-
(2001)
N Engl J Med
, vol.344
, pp. 1888-1894
-
-
Topol, E.J.1
Moliterno, D.J.2
Herrmann, H.C.3
-
17
-
-
0035967496
-
Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: Results of the GOLD (AU-Assessing Ultegra) multicenter study
-
S.R. Steinhubl, J.D. Talley, and G.A. Braden Point-of-care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention: results of the GOLD (AU-Assessing Ultegra) multicenter study Circulation 103 2001 2572 2878
-
(2001)
Circulation
, vol.103
, pp. 2572-2878
-
-
Steinhubl, S.R.1
Talley, J.D.2
Braden, G.A.3
-
18
-
-
0037114844
-
Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban
-
D.J. Schneider, H.C. Herrmann, and N. Lakkis Enhanced early inhibition of platelet aggregation with an increased bolus of tirofiban Am J Cardiol 90 2002 1421 1423
-
(2002)
Am J Cardiol
, vol.90
, pp. 1421-1423
-
-
Schneider, D.J.1
Herrmann, H.C.2
Lakkis, N.3
-
19
-
-
0037310526
-
Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban
-
D.J. Schneider, H.C. Herrmann, and N. Lakkis Increased concentrations of tirofiban in blood and their correlation with inhibition of platelet aggregation after greater bolus doses of tirofiban Am J Cardiol 91 2003 334 336
-
(2003)
Am J Cardiol
, vol.91
, pp. 334-336
-
-
Schneider, D.J.1
Herrmann, H.C.2
Lakkis, N.3
-
20
-
-
0035897888
-
Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: The GUSTO V randomised trial
-
E.J. Topol Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial Lancet 357 2001 1905 1914
-
(2001)
Lancet
, vol.357
, pp. 1905-1914
-
-
Topol, E.J.1
-
21
-
-
0037032380
-
Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial
-
A.M. Lincoff, R.M. Califf, and F. Van de Werf Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial JAMA 288 2002 2130 2135
-
(2002)
JAMA
, vol.288
, pp. 2130-2135
-
-
Lincoff, A.M.1
Califf, R.M.2
Van De Werf, F.3
-
22
-
-
0035949117
-
Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: The ASSENT-3 randomised trial in acute myocardial infarction
-
The ASSENT-3 Investigators
-
The ASSENT-3 Investigators Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction Lancet 358 2001 605 613
-
(2001)
Lancet
, vol.358
, pp. 605-613
-
-
|